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Abstract
Background: Generalized hypoxic pulmonary vasoconstriction (HPV) occurring during exposure to hypoxia is a 
detrimental process resulting in an increase in lung vascular resistance. Nebulization of sodium nitrite has been shown 
to inhibit HPV. The aim of this project was to investigate and compare the effects of nebulization of nitrite and different 
formulations of acidified sodium nitrite on acute HPV.
Methods: Ex vivo isolated rabbit lungs perfused with erythrocytes in Krebs-Henseleit buffer (adjusted to 10% 
hematocrit) and in vivo anesthetized catheterized rabbits were challenged with periods of hypoxic ventilation 
alternating with periods of normoxic ventilation. After baseline hypoxic challenges, vehicle, sodium nitrite or acidified 
sodium nitrite was delivered via nebulization. In the ex vivo model, pulmonary arterial pressure and nitric oxide 
concentrations in exhaled gas were monitored. Nitrite and nitrite/nitrate were measured in samples of perfusion buffer. 
Pulmonary arterial pressure, systemic arterial pressure, cardiac output and blood gases were monitored in the in vivo 
model.
Results: In the ex vivo model, nitrite nebulization attenuated HPV and increased nitric oxide concentrations in exhaled 
gas and nitrite concentrations in the perfusate. The acidified forms of sodium nitrite induced higher levels of nitric 
oxide in exhaled gas and had longer vasodilating effects compared to nitrite alone. All nitrite formulations increased 
concentrations of circulating nitrite to the same degree. In the in vivo model, inhaled nitrite inhibited HPV, while 
pulmonary arterial pressure, cardiac output and blood gases were not affected. All nitrite formulations had similar 
potency to inhibit HPV. The tested concentration of appeared tolerable.
Conclusion: Nitrite alone and in acidified forms effectively and similarly attenuates HPV. However, acidified nitrite 
formulations induce a more pronounced increase in nitric oxide exhalation.
Background
Hypoxia-induced pulmonary arterial vasoconstriction is
an important physiologic mechanism leading to redistri-
bution of blood flow from poorly ventilated areas of the
lung to better ventilated ones in an attempt to optimize
ventilation-perfusion matching [1]. Generalized HPV,
which occurs during exposure to hypoxia or at high alti-
tudes, is a pathophysiologic process resulting in an acute
increase in pulmonary vascular resistance, right ventricu-
lar overload, and restriction of right ventricular function
[2]. Chronic hypoxic exposure, which accompanies lung
diseases such as chronic obstructive pulmonary disease
and pulmonary arterial hypertension, results in sustained
HPV and vascular remodeling, which in turn leads to
acceleration of right ventricular failure [3]. Therefore,
resolution of HPV is a viable strategy for treatment of
these patients.
NO is a potent endothelial-derived vasodilating agent
[4]. Inhaled administration of exogenous NO has a vaso-
dilatory effect that is selective for the pulmonary vascula-
ture [5]. Moreover, activation of the NO-cGMP signaling
pathway has been shown to attenuate HPV [6] and has
antiproliferative effects [7].
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because it may represent an endogenous store of NO [8].
Enzymes having nitrite reductase activity include deoxy-
hemoglobin [9] and xanthine oxidoreductase [10]. Non-
enzymatic NO generation from nitrite under acidic con-
ditions [11] in the stomach or due to reaction with ascor-
bic acid has also been demonstrated [12,13]. Further,
nitrite reduction to NO in a physiologically acidic envi-
ronment (pH 6.66) has been shown to relax isolated aor-
tic rings. This effect was augmented in the presence of
ascorbic acid [14].
However, the hemodynamic importance of these mech-
anisms is still subject of debate because the NO-produc-
ing activity of deoxyhemoglobin can be overwhelmed by
the NO-scavenging properties of hemoglobin [15]. On
the other hand, nitrite delivered to the lungs of newborn
sheep by nebulization induced NO release and inhibited
HPV [16]. Moreover, increased blood flow after nitrite
infusion has been demonstrated in humans [17,18]. Topi-
cal administration of acidified nitrite formulations has
been shown to increase blood flow in skin [19].
Thus, mammals have both nitrite reducing systems to
promote vasodilation and systems capable of blunting
this vasodilating effect. The aim of this study was to test
whether application of acidified sodium nitrite formula-
tions could inhibit HPV in an ex vivo and in vivo rabbit
model and if there are differences in the effects of nitrite
alone and acidified formulations. Additionally, we sought
to test the possibility of restricting the vasodilating effect
of nitrite to the pulmonary vasculature by nebulization of
the nitrite formulations [20].
Methods
Chemicals and reagents
Krebs-Henseleit buffer contained 120 mM NaCl, 4.3 mM
KCl, 1.1 mM KH2PO4, 24 mM NaHCO3, 2.4 mM CaCl2,
1.3 mM MgCl2, and 13.32 mM glucose as well as 5% (wt/
vol) hydroxyethylamylopectin (mol wt 200,000) and was
purchased from Serag-Wiessner (Naila, Germany).
Sodium nitrite, citric acid, ascorbic acid and saccharin
were obtained from Aires Pharmaceuticals (San Diego,
USA). Griess reagent (modified) and vanadium chloride
were obtained from Sigma (Munich, Germany).
Animals
All animal experiments were approved by local authori-
ties. Male New Zealand White Rabbits (body weight 3.33
± 0.24 kg) were used. Animals were kept under pathogen-
free conditions and handled in accordance with the Euro-
pean Communities recommendations for experimenta-
tion.
Isolated lung model
The technique of isolated rabbit lung perfusion has been
described [21]. Briefly, rabbits were anticoagulated intra-
venous administration of heparin 1,000 U/kg and deeply
anesthetized with ketamine and xylazine. The lungs were
removed from the thorax without interrupting ventila-
tion and perfused and freely suspended from a force
transducer for monitoring organ weight in a humidified
chamber at 39°C. In a recirculating system, the flow was
slowly increased to 100 ml/min (total volume 250 ml).
Left atrial pressure was set at 2 mmHg (referenced at the
hilum), and the entire system was equilibrated at 37°C.
Pressures in the pulmonary artery and left atrium were
registered with pressure transducers, and data were con-
tinuously transferred to a computer for online monitor-
ing. Inclusion criteria for the study were 1) a
homogeneous white appearance of the lungs with no
signs of edema, hemostasis or atelectasis; 2) initial Ppa
and ventilation pressure values in the normal range; and
3) a constant organ weight during an initial steady-state
period of at least 20 minutes. Figure 1 illustrates the basic
design of the experiments.
Erythrocyte isolation
During lung preparation, blood was collected by punctur-
ing the left ventricle. After centrifugation for 10 minutes
at 300 × g, the buffy coat was removed. The remaining
erythrocytes were washed by mixing with Krebs-
Henseleit buffer (1:1 ratio) and re-centrifuged. Superna-
tant was removed, and sedimented erythrocytes were
admixed with re-circulating buffer according to the pro-
tocol (see Figure 1).
Experimental protocol
After the initial steady-state period, washed autologous
erythrocytes were admixed with recirculating buffer to
achieve a level of 10% hematocrit. A blood transfusion fil-
ter (Pall, Dreieich, Germany) was used to remove eryth-
rocyte aggregates from circulation. After a 50-minute
stabilization period, hypoxic challenges were initiated by
switching the inhaled gas mixture to a hypoxic mixture of
3% O2, 5.3% CO2, and 94.7% N2 (Messer, Siegen, Ger-
many). In dose-escalation experiments, after the first two
hypoxic maneuvers every hypoxic challenge was accom-
panied by nebulization of sodium nitrite in increasing
concentrations. Dosages tested were 1 μg/ml, 10 μg/ml,
100 μg/ml, 1 mg/ml, 5 mg/ml and 10 mg/ml. Dosages
were calculated in ALF.
The experimental protocol for testing different formu-
lations is presented in Figure 1. Six sequential hypoxic
maneuvers of 15 minutes duration interrupted by 15-
minute periods of normoxic ventilation were conducted.
During the third hypoxic challenge, nebulization was car-
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(Respironics, Herrsching, Germany) either with PB (0.05
mM) or different sodium nitrite formulations dissolved in
PB.
Lungs were treated with one of the following formula-
tions:
1. PB: 1 ml 0.05 mM PB. The pH of the solution was 
7.8-7.9;
2. Nitrite: 1 ml of the 0.05 mM PB containing 220 mM 
sodium nitrite and 0.25 mM sodium saccharin. The 
pH of the solution was 7.7-7.8;
3. Nitrite + citric acid: 1 ml of 0.05 mM PB containing 
220 mM sodium nitrite, 1.56 mM citric acid, and 0.25 
mM sodium saccharin. The pH of the solution was 
5.4-5.5;
4. Nitrite + citric acid + ascorbic acid: 1 ml of 0.05 
mM PB containing 220 mM sodium nitrite, 1.56 mM 
citric acid, 0.5 mM ascorbic acid, and 0.25 mM 
sodium saccharin. The pH of the solution was 5.4-5.5.
Nebulization of these formulations of sodium nitrite
resulted in nitrite concentrations in ALF of approxi-
mately 1 mg/ml. This concentration is based on the vol-
ume of ALF in our experimental setup, found to be 2.5 ml
[22], and the delivery efficiency of our nebulization sys-
tem at approximately 25%, estimated by weighing the
nebulizer system before and after nebulization.
Measurement of Noex
Measurements were performed as described by Spri-
estersbach et al. [23]. Briefly, aliquots of exhaled gas were
taken continuously for measurement by chemilumines-
cence using a Sievers 280 NO Analyzer (Seeheim/Ober-
Beerbach, Germany).
Measurement of nitrite and nitrate in perfusate
Nitrite in the perfusate samples was measured using
Griess reagent according to manufacturer's instructions
(Sigma, Munich, Germany). Briefly, perfusate was sam-
pled from venous effluent at the times illustrated in
Scheme 1. After centrifugation, the supernatant was ali-
quoted, frozen immediately, and stored at -20°C until
analysis. For measurement of nitrite, 100 μl of perfusate
was mixed with 100 μl of Griess reagent. After 15-minute
incubation at room temperature, the absorbance at 540
nm was measured. The nitrite concentration in experi-
mental samples was calculated by comparing values
against a calibration curve. Calibration curve was gener-
ated by serial dilutions of sodium nitrite of known con-
centrations in the same buffer as used for experiments.
To measure nitrite and nitrate levels, samples were incu-
bated with Griess reagent for 10 minutes, and then 100 μl
vanadium chloride was added. After 35-minute incuba-
tion at 36°C, the absorbance was measured.
Wet to dry ratio determination
At the completion of perfusion experiments, pieces of
lung tissue from every lobe were cut. Samples were
weighed and dried in an oven at 60°C for 7-9 days until
the weight stabilized. Initial weight (wet) was divided by
final weight (dry).
Figure 1 Timescale of ex vivo experimental setup. A total of six hypoxic maneuvers (3% O2 in an inhaled gas mixture) were performed. The second 
hypoxic maneuver was used as a control, because the second and subsequent hypoxic maneuvers induced HPV of stable and reproducible strength. 
Nebulization was initiated at the onset of the third hypoxic maneuver. In dose titration experiments, nitrite nebulizations were performed beginning 
with the third maneuver. The concentration that was delivered increased with each subsequent nebulization.
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Techniques for the measurement of invasive hemody-
namics are described elsewhere [24]. Briefly, rabbits were
anesthetized with xylazine (2.1 mg/kg) and ketamine (7
mg/kg), followed by a constant intravenous infusion of
xylazine (25 mg/kg/h) and ketamine (80 mg/kg/h) (Injec-
tomat S; Fresenius, Bad Hamburg, Germany) through the
right peripheral ear vein. Rabbits were anticoagulated
with heparin (200 U/kg), tracheostomized and ventilated
with an FIO2 of 0.5 using a Harvard respirator (cat/rabbit
ventilator; Hugo Sachs Elektronik, March Hugstetten,
Germany). Frequency was set at 40 breaths/min, tidal
volume at 8 ml/kg, and PEEP at 0.5 mmHg resulting in a
paCO2 range of 35-45 mmHg. A catheter was inserted
into the left carotid artery and connected to a pressure
transducer for arterial pressure monitoring. The right
femoral vein was cannulated for infusion of saline. A bal-
loon-tipped pulmonary artery catheter (Berman angio-
graphic balloon catheter AI-07134, 4F; Arrow, Reading,
PA) was inserted into the pulmonary artery through the
right external jugular vein.
Hemodynamics and blood gases
Ppa and mean Psa were continuously recorded using
fluid-filled pressure transducers (Braun; Combitrans,
Melsungen, Germany). The level of the left atrium was
the zero reference for measurements. CO was calculated
by the Fick's principle, employing the mixed venous oxy-
gen content, arterial oxygen content, and oxygen uptake.
Oxygen uptake of the animals was measured online (O2
controller; Labotect, Göttingen, Germany). Arterial and
mixed venous samples were collected (1 ml) and main-
tained on ice until analyzed for pO2, pH, and pCO2
(ABL330; Radiometer, Copenhagen, Denmark). Hemo-
globin and oxygen saturation were measured using an
OSM2 hemoximeter (Radiometer).
Experimental protocol
After the initial steady-state period, hypoxic challenges
were initiated by reducing the FIO2 to 0.15. Six sequential
hypoxic maneuvers of 15 minutes duration were inter-
rupted by 15-minute periods of normoxic ventilation.
During the third hypoxic challenge, nebulization of either
PB (0.05 mM) or different sodium nitrite formulations
dissolved in PB was performed. Blood samples for gas
analysis were drawn during the steady-state period and
during hypoxic challenges with ongoing nebulization.
Data analysis
Data are expressed as mean ± s.e.m. For multiple compar-
isons, one-way analysis of variance followed by a post-
hoc test (Student-Newman-Keuls) was used. To evaluate
intra-group differences, a paired t-test was used. P values
< 0.05 were considered significant.
Results
Nitrite nebulization reduces HPV in the rabbit ex vivo model
Ventilation with 15-minute periods of hypoxia induced
acute pulmonary vasoconstriction (Figure 2, 3). All
hypoxic challenges, except the first, induced reproducible
vasoconstriction. Therefore, the second HPV response
was used as a reference. Nebulization of sodium nitrite or
vehicle was performed during the third hypoxic chal-
lenge, and experiments were complete after the sixth
hypoxic challenge. Initial experiments were performed to
determine the concentration of sodium nitrite needed for
a significant change in Ppa. In these dose escalation
experiments, sodium nitrite at both 1 and 10 mg/ml in
ALF was found to reduce the HPV response (Figure 2A).
However, nitrite at 10 mg/ml induced a significant
increase in lung weight during nebulization, suggesting
toxicity (Figure 2B) and therefore a dose of 1 mg/ml was
chosen for the remaining experiments. Sodium nitrite
effectively reduced the strength of HPV, whereas nebuli-
zation with PB had no discernable effect on HPV (Figure
3).
Acidified preparations appeared to have a more pro-
nounced effect on Ppa compared to sodium nitrite alone.
Importantly, a single nebulization of nitrite reduced the
strength of HPV by 50.9% ± 8.8%. This effect lasted for
three hypoxic challenges. These results indicated that
sodium nitrite in acidified preparations may have a more
sustained effect on HPV than sodium nitrate alone (Fig-
ure 3) as evidenced by significant reductions throughout
the last hypoxic challenge (i.e., the entire length of the
study).
NOex was monitored after nebulization of the various
sodium nitrite preparations. Nitrite nebulization signifi-
cantly increased the concentration of NOex during nebu-
lization. The combination of sodium nitrite with citric
acid or ascorbic acid induced a more pronounced
increase in the concentration of NOex compared to
sodium nitrite alone (Figure 3A). NOex concentrations
remained elevated in all nitrite nebulization groups until
termination of the experiment (nitrite group 27.9 ± 1.3
ppb and PB group 17.4 ± 2.1 ppb at the end of experi-
ment, p = 0.009). However, during the hypoxic maneu-
vers, changes in NOex were similar in all groups (Figure
4B).
Nitrite nebulization resulted in a rapid increase in
nitrite and nitrate concentrations in recirculating buffer
(Figure 5), whereas PB nebulization did not. Different for-
mulations of sodium nitrite increased the nitrite level in
perfusion buffer to the same extent. Nebulization of
sodium nitrite from these formulations did not alter fluid
retention in lungs, as assessed by the absence of changes
in the wet to dry ratio (Figure 6).
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Figure 2 Dose titration for nebulized nitrite in the isolated perfused lung model. Nitrite was nebulized in increasing concentrations during hy-
poxic maneuvers. (A) HPV was calculated as the difference between the maximum Ppa during hypoxia and the Ppa during normoxia. (B) Lung weight 
gain during nebulization. Lungs were freely suspended from a force transducer for monitoring organ weight in a humidified chamber at 39°C. Weight 
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A second series of experiments was performed in lungs of
live rabbits. All rabbits demonstrated stable hemodynam-
ics during experiments without the need for support with
adrenomimetics. We chose a level of hypoxia that
induced pronounced HPV without significantly changing
Psa. Hypoxic maneuvers induced a rapid decrease in
paO2 from 260.7 ± 3.6 mmHg to 45.1 ± 1.8 mmHg.
Results were similar in all groups. SaO2 decreased from
99.7 ± 0.01% to 86.5 ± 1.6%. This induced acute and
reversible HPV (Table 1), which was accompanied by a
slight decrease in Psa. Nebulization of sodium nitrite and
its acidified forms effectively reduced HPV to one-third
of its initial value (Table 1). In groups receiving nebulized
sodium nitrite, the strength of HPV during subsequent
hypoxic challenges remained slightly reduced.
Notably, nitrite nebulization did not influence Psa and
did not augment hypoxia-induced decreases in Psa. How-
ever, acidified nitrite slightly, but not significantly, aug-
mented hypoxia-induced decreases in Psa during the
third hypoxic maneuver (Table 1). CO was comparable in
all groups. Sodium nitrite nebulization did not affect CO
(Table 1).
Discussion
We sought to test whether inhalation of acidified sodium
nitrite formulations could reduce the extent of hypoxia-
induced vasoconstriction. Further, we examined whether
acidified formulations had more pronounced vasodila-
tory effects than nitrite alone as a result of the synergistic
action of two different nitrite-reducing mechanisms. The
main finding of our study is that both nebulized nitrite
alone and acidified formulations effectively reduced the
strength of HPV in both ex vivo and in vivo models of
acute HPV.
Hunters et al. observed increased NOex and reduced
HPV after nitrite nebulization in lambs [16]. These data
suggest that inhaled application of nitrite induces prefer-
ential vasodilation in the pulmonary circulation, operat-
ing via deoxyhemoglobin oxidation by nitrite with NO
generation, a mechanism described by Doyle et al. [25].
However, Deem et al. demonstrated that, although this
mechanism is operational during hypoxia, its effect is
Figure 3 Effect of nebulized nitrite and acidified forms of nitrite on the strength of HPV in the isolated perfused lung model. The strength 
of HPV is represented as the difference between the maximum Ppa during hypoxia and the Ppa during normoxia. * p < 0.05 vs. PB.
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Figure 4 Impact of nitrite nebulization on the concentration of exhaled NO in the isolated perfused lung model. (A) Exhaled NO was moni-
tored online from the exhaled gas mixture. (B) Hypoxic challenges induced a rapid and reversible decrease in NOex. Nitrite nebulization increased 
NOex during the hypoxic phase. Values represent the difference between NOex concentrations during hypoxia and during the preceding normoxic 
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Figure 5 Changes in nitrite and nitrite/nitrate (NOx) concentration in perfusate after nebulization. Perfusate samples were collected as depict-
ed in Scheme 1. Samples were immediately frozen and stored at -20°C until analysis. Measurements were performed using a modified Griess reagent 
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globin [15]. These findings suggest limited efficacy of the
mechanism of nitrite reduction by deoxyhemoglobin for
the treatment of patients. On the other hand, nitrite
reductase activity of other enzymes expressed in the lung,
for instance xanthine oxidase and mitochondrial respira-
tory chain, has been described [26]. Combined, these
findings could represent an important mechanism
responsible for nitrite-induced vasodilation.
Recently, a non-enzymatic pathway of NO generation,
resulting from nitrite dysproportionation under acidic
pH during anoxia, has gained attention [27]. The highest
yield of NO production in anoxic myocardium was found
to occur at pH 5.5 [28]. Moreover, topical administration
of acidified nitrite formulations induced local vasodila-
tion, presumably resulting from enhanced NO generation
[19]. NO generation at acidic pH was potentiated in the
presence of ascorbic acid, which led to greater vasodila-
tion.
In accordance with the findings of other investigators,
we observed that nebulization of nitrite to ventilated rab-
bit lungs during hypoxic challenge significantly reduced
HPV. Inhibition of vasoconstriction was associated with
increased NOex during nitrite nebulization.
The combination of nitrite and citric acid or citric acid
and ascorbic acid resulted in acidic formulations with pH
values of 5.3-5.4. This pH range was chosen to achieve
the maximal rate of non-enzymatic NO generation. The
acidification of nitrite solutions led to spontaneous NO
generation in vitro (data not shown), in accordance with
the mechanism of nitrite dysproportionation described
by Zweier et al. [27]. Nebulization of the acidified nitrite
formulations to isolated lungs induced a more pro-
nounced increase in NOex than the solution of nitrite
alone. Further, acidified formulations induced longer-
lasting vasodilation than nitrite alone, although they
reduced HPV to the same degree as sodium nitrite. Nota-
bly, nitrite nebulization induced a dramatic increase in
NOex lasting for 10 minutes. Levels of NOex remained
elevated until the termination of the experiment in all
nitrite nebulization groups.
Figure 6 Impact of nitrite nebulization on lung wet to dry ratio. At the end of each experiment, pieces of lung tissue from every lobe were cut. 
Samples were weighed and dried in an oven at 60°C for 7-9 days until the weight stabilized. Initial weight (wet) was divided by final (dry) weight.
Egemnazarov et al. Respiratory Research 2010, 11:81
http://respiratory-research.com/content/11/1/81
Page 10 of 12Nebulization of nitrite led to a rapid and sustained
increase in nitrite concentration in recirculating buffer.
The maximum concentration of nitrite in the buffer was
71.3 ± 7.0 μM, which is within the range of effective vaso-
dilating concentrations of nitrite described by others
[14,29,30]. Higher concentrations of circulating nitrite (as
achieved by nebulization) induced lung weight gain. The
physiological significance of the elevated level of nitrite in
the buffer is not clear. It could represent a depot that
delivers and releases nitrite on demand. Conversely,
according to the mechanism described by Doyle et al.
[25], subsequent hypoxic challenges should lead to deox-
ygenation with deoxyhemoglobin formation, a process
that converts nitrite to NO. Indeed, we observed that in
all subsequent hypoxic challenges HPV was slightly
lower, although this reduction did not reach statistical
significance. However, enhanced NOex, as a result of
reaction between sodium nitrite and deoxyhemoglobin
during hypoxic maneuvers, was not observed (Figure 3B).
Using the 1 mg/ml formulations, significant fluid accu-
mulation in the lung after nitrite nebulization was not
observed, suggesting that nitrite in the concentration
used in this study had no adverse effect on the lung.
In the in vivo experiments, sodium nitrite nebulization
effectively reduced the strength of HPV in the first
hypoxic challenge following nebulization. The effect of
both sodium nitrite alone and acidified nitrite formula-
tions lasted for only 15 minutes, although HPV remained
slightly reduced during subsequent hypoxic challenges
until termination of the experiment. CO did not change
significantly during the nitrite nebulization experiments.
In contrast to intravenous injection of nitrite, which
induces both pulmonary and systemic vasodilation [31],
nebulized sodium nitrite induced vasodilation in the lung
with no appreciable effect on systemic hemodynamics.
However, nebulization of acidified formulations of nitrite
slightly augmented hypoxic vasodilation of systemic ves-
sels.
In summary, we observed higher levels of NOex in
experiments involving acidified nitrite nebulization.
However, we did not observe further enhancement of the
HPV-inhibiting effect. Notably, we observed slightly
more systemic vasodilation in the acidified nitrite group.
However, this effect did not reach statistical significance.
Nevertheless, this could be an important consideration in
patients suffering from pulmonary hypertension who
have limited cardiac reserve and borderline systemic
hypotension. One possible explanation is that acidified
nitrite is not as dependant as non-acidified nitrite from
the local microenvironment and deoxyhemoglobin for-
mation. Therefore, the effects of acidified nitrite formula-
tions may be not restricted to the hypoxic areas of the
lung.
We used the ex vivo model of isolated perfused rabbit
lung for dose calibration and pharmacokinetic studies.
The limitation of this model is that pharmacokinetic and
pharmacodynamic data obtained in this manner do not
reflect the influence of metabolism and excretion by kid-
Table 1: The effect of nebulized nitrite and acidified forms of nitrite on the strength of HPV, Psa and CO in the in vivo model 
of catheterized rabbits.
PB PB + nitrite PB + nitrite + citrate p value
HPV Baseline
(mmHg)
1.24 ± 0.58 1.56 ± 0.38 1.79 ± 0.50 n.s.
Nebulization
(mmHg)
1.36 ± 0.50 0.52 ± 0.39 0.69 ± 0.72 p < 0.05





-6.78 ± 1.97 -6.07 ± 0.64 -7.39 ± 2.61 n.s.
Nebulization
(mmHg)
-6.36 ± 1.27 -5.28 ± 1.39 -8.16 ± 0.85 n.s.
Cardiac output Baseline
(ml/min)
617.63 ± 15.96 725.64 ± 39.59 575.46 ± 34.64 n.s.
Nebulization
(ml/min)
556.79 ± 37.62 589.46 ± 33.28 533.05 ± 28.16 n.s.
HPV was calculated as the difference between the maximum Ppa during hypoxia and the Ppa during normoxia. For percentage calculations, 
the strength of HPV during the second hypoxic challenge was set to 100%, and the value of HPV during nebulization was related to it. Nitrite 
alone and in acidified forms nebulized during the third hypoxic maneuver significantly inhibited HPV. CO was measured by Fick's method. 
Blood samples for analysis were drawn during normoxia and at the end of the third hypoxic challenge. Psa was monitored continuously using 
a catheter placed in the left carotid artery. Values represent the difference between Psa during normoxia and Psa during subsequent hypoxia.
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shorter duration of the inhibitory effects of nebulized
nitrite on HPV. This may reflect different pharmacoki-
netics in vivo. Nevertheless, our results obtained from the
in vivo model demonstrate that the mechanism described
is operational in vivo and has physiological relevance.
Conclusions
In the isolated lung preparation, both of the acidified
nitrite formulations we used, as well as nitrite alone,
effectively and similarly attenuated HPV with a trend
toward a more sustained effect with acidified formula-
tions. NOex increased when nitrite was prepared in an
acidic buffer, suggesting a potential means for better effi-
cacy. The concentrations of nitrite we tested appeared
tolerable. Nebulization of the nitrite or acidic nitrite for-
mulations preferentially induced vasodilation of the pul-
monary vasculature with no appreciable effect on
systemic arterial pressure or cardiac output in vivo.
List of used abbreviations
ALF: alveolar lining fluid; PB: phosphate buffer; CO: car-
diac output; FIO2: fraction of inspired oxygen; HPV:
hypoxic pulmonary vasoconstriction; NO: nitric oxide;
NOex: exhaled nitric oxide; NOx: nitrate and nitrite; Ppa:
pulmonary arterial pressure; Psa: systemic arterial pres-
sure; SaO2: oxygen saturation of hemoglobin; PEEP: posi-
tive end-expiratory pressure.
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